eFFECTOR Therapeutics, Inc. Operating Cash Flow
eFFECTOR Therapeutics, Inc. reported Operating Cash Flow of -$7.28 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2024-05-09
- eFFECTOR Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2024-03-31 was -$7.28M.
- eFFECTOR Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2023-12-31 was -$5.57M.
- eFFECTOR Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2023-09-30 was -$7.75M.
- eFFECTOR Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2023-06-30 was -$8.59M.
- eFFECTOR Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$29.55M.
- eFFECTOR Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$25.90M.
- eFFECTOR Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2021 was -$24.89M, a 279.89% decline from fiscal 2020.
- eFFECTOR Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2020 was $13.84M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2024-03-31 | -$7.28M 10-Q · filed 2024-05-09 | -$12.84M derived: sum of 2 quarters · filed 2024-05-09 | -$20.60M derived: sum of 3 quarters · filed 2024-05-09 | -$29.19M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-12-31 | -$5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$13.32M derived: sum of 2 quarters · filed 2024-03-26 | -$21.91M derived: sum of 3 quarters · filed 2024-03-26 | -$29.55M 10-K · filed 2024-03-26 | ||
| 2023-09-30 | -$7.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$16.35M derived: sum of 2 quarters · filed 2023-11-13 | -$23.98M 10-Q · filed 2023-11-13 | -$30.76M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-06-30 | -$8.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$16.23M 10-Q · filed 2023-08-08 | -$23.01M derived: sum of 3 quarters · filed 2024-05-09 | -$31.19M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-03-31 | -$7.64M 10-Q · filed 2024-05-09 | -$14.42M derived: sum of 2 quarters · filed 2024-05-09 | -$22.60M derived: sum of 3 quarters · filed 2024-05-09 | -$27.04M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$6.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$14.96M derived: sum of 2 quarters · filed 2024-03-26 | -$19.40M derived: sum of 3 quarters · filed 2024-03-26 | -$25.90M 10-K · filed 2024-03-26 | ||
| 2022-09-30 | -$8.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$12.62M derived: sum of 2 quarters · filed 2023-11-13 | -$19.12M 10-Q · filed 2023-11-13 | -$24.13M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | -$4.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$10.94M 10-Q · filed 2023-08-08 | -$15.94M derived: sum of 3 quarters · filed 2023-08-08 | -$25.01M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | -$6.50M 10-Q · filed 2023-05-09 | -$11.51M derived: sum of 2 quarters · filed 2023-05-09 | -$20.57M derived: sum of 3 quarters · filed 2023-05-09 | -$26.39M derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$14.07M derived: sum of 2 quarters · filed 2023-03-08 | -$19.89M derived: sum of 3 quarters · filed 2023-03-08 | -$24.89M 10-K · filed 2023-03-08 | ||
| 2021-09-30 | -$9.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$14.88M derived: sum of 2 quarters · filed 2022-11-07 | -$19.88M 10-Q · filed 2022-11-07 | -$27.35M derived: sum of 4 quarters · filed 2022-11-07 | ||
| 2021-06-30 | -$5.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$10.81M 10-Q · filed 2022-08-09 | -$737.24K 10-Q · filed 2021-08-12 | -$18.28M derived: sum of 3 quarters · filed 2022-08-09 | -$25.70M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$5.00M 10-Q · filed 2022-05-10 | -$473.18K 10-Q · filed 2021-06-03 | -$12.46M derived: sum of 2 quarters · filed 2022-05-10 | -$19.88M derived: sum of 3 quarters · filed 2022-05-10 | ||
| 2020-12-31 | -$7.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$14.88M derived: sum of 2 quarters · filed 2022-03-16 | $13.84M 10-K · filed 2022-03-16 | |||
| 2020-09-30 | -$7.42M derived: 10-Q 9 month − 8-K 6 month · filed 2021-11-08 | $21.30M 10-Q · filed 2021-11-08 | ||||
| 2020-06-30 | $28.72M 8-K · filed 2021-08-31 |